HUTCHMED (China) Limited (HCM) News
Track canonical SquawkNews coverage tagged to HCM, HUTCHMED (China) Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 9 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
HCM - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
HCM - HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026
GEOPOLITICS | Sep 24, 2026, 12:00 AM UTC
H
HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript
HUTCHMED (China) (NASDAQ: HCM ) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire
LIVE | Sep 18, 2026, 07:54 AM UTC
L
Hutchmed announces licensing agreement with GSK for KRAS-EGFR therapy
Hutchmed said it has announced a licensing agreement with GSK for a KRAS-EGFR antibody conjugate cancer therapy.
EQUITY | Sep 03, 2026, 04:00 AM UTC
L
Hutchmed says SANOVO trial shows PFS benefit with ORPATHYS+TAGRISSO in China
Hutchmed said its SANOVO trial showed a progression-free survival benefit for ORPATHYS plus TAGRISSO in treatment-naïve patients with MET-overexpressing EGFR-mutated lung cancer in China.
GEOPOLITICS | Aug 31, 2026, 12:00 AM UTC
M
HUTCHMED gets NMPA approval for ATLED in FGFR2 intrahepatic cholangiocarcinoma
Hutchmed announced NMPA approval for ATLED (fanregratinib) for treating FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma patients.
EQUITY | Aug 28, 2026, 12:00 AM UTC
M
HUTCHMED’s ORPATHYS plus TAGRISSO shows OS and PFS gains after TAGRISSO progression
HUTCHMED (HCM) says ORPATHYS® plus TAGRISSO® demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression
EQUITY | Aug 17, 2026, 12:00 AM UTC
L
HCM - HUTCHMED Reports 2026 Interim Results
HCM - HUTCHMED Reports 2026 Interim Results
EQUITY | Jul 30, 2026, 11:00 AM UTC
L
HUTCHMED Says China Grants Conditional Approval For ORPATHYS In MET-Amplified Gastric And Gastroesophageal Junction Cancer
HUTCHMED Says China Grants Conditional Approval For ORPATHYS In MET-Amplified Gastric And Gastroesophageal Junction Cancer
GEOPOLITICS | Jul 02, 2026, 08:46 AM UTC
M
HCM Presents Fanregratinib Data
HUTCHMED presents pivotal phase II data for fanregratinib in intrahepatic cholangiocarcinoma at ESMO Gastrointestinal Cancers Congress 2026
EQUITY | Jun 25, 2026, 12:30 AM UTC